Kringle Pharma, Inc. (JP:4884)
:4884
Want to see JP:4884 full AI Analyst Report?
Top Page
Kringle Pharma, Inc.
(4884)
Select Model
Select Model
Rating:43Neutral
Price Target:
¥323.00
▼(-14.78% Downside)
Action:Reiterated
Date:06/05/26
The score is held down primarily by weak financial performance (persistent losses and cash burn) and bearish technicals (price below all key moving averages with negative momentum). The main positive offset is the low financial leverage/no-debt balance sheet, but valuation support is limited given negative earnings and no dividend data.
Positive Factors
Proprietary HGF platform and focused pipeline
Kringle’s proprietary HGF technology and pipeline focus create a durable competitive advantage in regenerative and neurodegenerative therapeutics. Owning core biology reduces dependence on third-party platforms, supports differentiated assets for partnerships, and underpins long-term value if clinical progress validates mechanism.
Negative Factors
Ongoing cash burn and weak cash generation
Consistently negative operating cash flows indicate structural cash burn, forcing repeated external funding or dilutive financing. Over a 2–6 month horizon this weak cash-generation profile limits strategic options, increases funding risk, and can pressure R&D pacing or partnership terms if milestones require cash.
Read all positive and negative factors
Positive Factors
Negative Factors
Proprietary HGF platform and focused pipeline
Kringle’s proprietary HGF technology and pipeline focus create a durable competitive advantage in regenerative and neurodegenerative therapeutics. Owning core biology reduces dependence on third-party platforms, supports differentiated assets for partnerships, and underpins long-term value if clinical progress validates mechanism.
Read all positive factors
Kringle Pharma, Inc. (4884) vs. iShares MSCI Japan ETF (EWJ)
Market Cap
¥2.77B
Dividend YieldN/A
Average Volume (3M)51.60K
Price to Earnings (P/E)―
Beta (1Y)0.63
Revenue Growth0.12%
EPS Growth1.88%
CountryJP
Employees15
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-133.99
Shares Outstanding8,383,200
10 Day Avg. Volume53,170
30 Day Avg. Volume51,600
Financial Highlights & Ratios
PEG Ratio-0.26
Price to Book (P/B)2.41
Price to Sales (P/S)43.77
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Kringle Pharma, Inc. Business Overview & Revenue Model
Company Description
Kringle Pharma, Inc. specializes in the innovation, production, and distribution of hepatocyte growth factor (HGF) protein-based therapeutics aimed at regenerative medicine. The company's cutting-edge HGF solutions are designed to address serious ...
How the Company Makes Money
Kringle Pharma, Inc. generates revenue primarily through funding from research grants, partnerships, and licensing agreements with other pharmaceutical and biotech companies. It monetizes its proprietary HGF technology by developing drug candidate...
Kringle Pharma, Inc. Financial Statement Overview
Summary
Income Statement
18
Very Negative
Balance Sheet
62
Positive
Cash Flow
20
Very Negative
| Breakdown | Sep 2025 | Sep 2024 | Sep 2023 | Sep 2022 | Sep 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 72.22M | 80.04M | 69.25M | 391.83M | 289.76M |
| Gross Profit | 72.22M | 0.00 | 0.00 | 303.42M | 218.16M |
| EBITDA | -909.45M | -817.88M | -888.76M | -426.17M | -357.88M |
| Net Income | -916.25M | -756.45M | -854.15M | -331.83M | -301.17M |
Balance Sheet | |||||
| Total Assets | 2.08B | 2.76B | 2.62B | 3.21B | 2.64B |
| Cash, Cash Equivalents and Short-Term Investments | 1.62B | 2.31B | 2.14B | 2.76B | 2.14B |
| Total Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Total Liabilities | 770.11M | 648.92M | 596.95M | 419.50M | 129.48M |
| Stockholders Equity | 1.31B | 2.11B | 2.02B | 2.79B | 2.51B |
Cash Flow | |||||
| Free Cash Flow | 0.00 | -661.17M | -689.10M | 15.80M | -560.92M |
| Operating Cash Flow | -755.78M | -661.17M | -689.10M | 15.80M | -560.92M |
| Investing Cash Flow | -154.01M | -121.36M | -120.88M | -254.38M | 0.00 |
| Financing Cash Flow | 84.14M | 838.23M | 69.16M | 603.11M | 595.90M |
Kringle Pharma, Inc. Technical Analysis
Negative
379.00
Price Trends
419.30
Negative
408.16
Negative
422.24
Negative
Market Momentum
-33.61
Positive
38.78
Neutral
45.09
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JP:4884, the sentiment is Negative. The current price of 379 is above the 20-day moving average (MA) of 352.95, below the 50-day MA of 419.30, and below the 200-day MA of 422.24, indicating a bearish trend. The MACD of -33.61 indicates Positive momentum. The RSI at 38.78 is Neutral, neither overbought nor oversold. The STOCH value of 45.09 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for JP:4884.
Kringle Pharma, Inc. Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
45 Neutral | ¥8.57B | -8.41 | -26.70% | ― | 60.80% | -8.89% | |
45 Neutral | ¥3.53B | -2.92 | ― | ― | 42.38% | 8.81% | |
43 Neutral | ¥2.77B | -2.57 | ― | ― | 0.12% | 1.88% | |
41 Neutral | ¥132.29B | -36.31 | -10.16% | ― | -59.19% | -124.16% | |
41 Neutral | ¥1.82B | -1.00 | ― | ― | ― | 28.49% | |
41 Neutral | ¥3.14B | -1.60 | ― | ― | -94.55% | 7.93% |
* Healthcare Sector Average
JP:4884
Kringle Pharma, Inc.
310.00
-584.00
-65.32%
JP:4587
Peptidream
959.80
-673.20
-41.22%
JP:4571
NanoCarrier Co., Ltd.
100.00
-51.00
-33.77%
JP:4591
Ribomic, Inc.
61.00
-41.00
-40.20%
JP:4598
Delta-Fly Pharma, Inc.
122.00
-510.00
-80.70%
JP:4881
FunPep Company Limited
60.00
-60.00
-50.00%
Kringle Pharma, Inc. Corporate Events
Kringle Pharma narrows revenue gains but deepens losses in first half of FY2026
May 11, 2026
Kringle Pharma reported modest net sales growth to ¥36 million for the six months ended March 31, 2026, but remained loss-making with an operating loss of ¥515 million and a net loss of ¥516 million, resulting in a negative earnings...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.